Leerink Partners maintained a Buy rating on Disc Medicine, Inc., while Thomas Smith worked for the firm.
1 report, 0 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners maintained a Buy rating on Disc Medicine, Inc., while Thomas Smith worked for the firm.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Thomas Smith
artist of the early 19th century
Nothing else this week.
-
Leerink partners
U.S. investment bank
Related events
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
Coverage
Newest first; wire copies grouped- Unknown outlet